Genmab (GMAB)
(Delayed Data from NSDQ)
$25.53 USD
-0.95 (-3.59%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $25.53 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Price, Consensus and EPS Surprise
GMAB 25.53 -0.95(-3.59%)
Will GMAB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GMAB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GMAB
AbbVie Stock Up Almost 20% in 3 Months: Buy, Sell or Hold?
AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use
GMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Genmab (GMAB) Could Surge 45.08%: Read This Before Placing a Bet
Buy 2 Biotech Bigwigs Set to Gain on Possible Earnings Beat
Should You Buy AbbVie (ABBV) After Q2 Beat, Guidance Raise?
Other News for GMAB
Genmab launches partnership with OpenAI for 'AI Everywhere'
Genmab A/S (0MGB) Gets a Buy from UBS
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
Genmab announces new data from Phase 1/2 study of Rina-S
Genmab resumed with an Equal Weight at Morgan Stanley